Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

0.2358 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,977
Open 0.2358
Bid (Size) 0.2359 (15)
Ask (Size) 0.2425 (1)
Prev. Close 0.2358
Today's Range 0.2358 - 0.2358
52wk Range 0.1830 - 8.170
Shares Outstanding 20,595,503
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
S&P 500 Tops 6,000; Rumble Shares Slide After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-96.99%
-96.99%
1 Month
-91.36%
-91.36%
3 Month
-84.98%
-84.98%
6 Month
-95.93%
-95.93%
1 Year
-94.63%
-94.63%

More News

Read More
Dow Jumps Over 150 Points; CyberArk Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
Via Benzinga
US Stocks Mixed; Inflation Rate Increases In October
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results
Via Benzinga
Exposures Fossil Fuels
S&P 500 Gains 1%; Home Depot Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
Via Benzinga
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Via Benzinga
Why Is Syros Pharmaceuticals (SYRS) Stock Down 62% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Why Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
From Syros Pharmaceuticals
Via Business Wire
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
From Syros Pharmaceuticals
Via Business Wire
SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.